PORTLAND, Ore. & CAMBRIDGE, Mass.—A master collaboration agreement is underway between Sysmex Corp. and MolecularMD Corp., under which the two diagnostics-focused companies will work together to develop a method for combining their capabilities in offering best-in-class, tailored solutions for the development and commercialization of companion diagnostics. Sysmex and MolecularMD are seeking to accelerate development and offer flexible structures for diagnostic test alignment with drug approval, and plan to apply their expertise in U.S. PMA, European CE, Japanese PMDA and APAC regulatory requirements to aid customers. A press release regarding the agreement notes that it could be expanded to include additional organizations.

 

Sysmex focuses on laboratory diagnostics, laboratory automation and clinical information systems—with an eye toward personalized medicine, the company has been exploring opportunities in liquid biopsy and companion diagnostics with proprietary diagnostic technologies and experiences. MolecularMD is a diagnostics company aimed at enabling the development and commercialization of precision medicines in oncology—its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted and immuno-oncology therapies.